Benocyclidine

Source: Wikipedia, the free encyclopedia.
(Redirected from
BTCP
)
Benocyclidine
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • 1-[1-(1-Benzothiophen-2-yl)cyclohexyl]piperidine
JSmol)
  • C1(SC(C2(CCCCC2)N3CCCCC3)=C4)=C4C=CC=C1
  • InChI=1S/C19H25NS/c1-5-11-19(12-6-1,20-13-7-2-8-14-20)18-15-16-9-3-4-10-17(16)21-18/h3-4,9-10,15H,1-2,5-8,11-14H2 checkY
  • Key:RGSVXQJPSWZXOP-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Benocyclidine, also known as benzo​thiophenyl​cyclo​hexylpiperidine (BTCP), is a psychoactive recreational drug of the arylcyclohexylamine class which is related to phencyclidine (PCP). It was first described in a patent application naming Marc Caron and colleagues at Duke University in 1997.[1]

It acts as a

dissociative effects.[2][3] It has been used to label the dopamine transporter.[4][5] BCP was used to try to find a common pharmacophore for DRI type stimulants.[6]

More recently, benocyclidine has been found in several ecstasy tablets, sold as MDMA.[7]

Legal status in the United States

Benocyclidine is a Schedule I controlled substance in the state of Florida and Virginia, making it illegal to buy, sell, or possess in these states.[8][9]

Otherwise, benocyclidine is not scheduled at the federal level in the

Federal Analog Act
if intended for human consumption.

See also

References

  1. ^ PCT Patent Application WO199712513 (see also US Patents Nos.5,866,756 and 6,218,595
  2. ^
    PMID 3384005
    .
  3. ^ .
  4. .
  5. .
  6. .
  7. ^ "EcstasyData Testing Result: Blue Butterfly". Ecstasy and other drug testing. Erowid Center. Retrieved 2 February 2012.
  8. ^ "§ 54.1-3446. Schedule I." Virginia Law. Retrieved 14 September 2023.
  9. ^ "Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL".
  10. ^ "21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I". Archived from the original on 2009-08-27. Retrieved 2014-12-17.
This page is based on the copyrighted Wikipedia article: BTCP. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy